Search research articles
Contact Us
Filters
Showing results (41-50 of 93) with videos related to
Page
of 10
Sort By:
Oncotarget
|
April 19, 2014
Pathways and therapeutic targets in melanoma
Emma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2024
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events
Limor Rubin, Aviv Talmon, Yaarit Ribak, et al.
Cancer Immunology, Immunotherapy : CII
|
June 27, 2009
Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells
Jacobus J Bosch, Uzoma K Iheagwara, Sarah Reid, et al.
Anticancer Research
|
February 27, 2026
Autologous Tumor Vaccination in Melanoma and Colon Cancer Patients With Recurrent Liver Metastases: A Case Series
Ofra Maimon, Benjamin Nisman, Inna Ben-David, et al.
Frontiers in Immunology
|
September 22, 2023
The future of affordable cancer immunotherapy
Niels Schaft, Jan Dörrie, Gerold Schuler, et al.
Journal of Virology
|
October 30, 2009
The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
Itay Lazar, Barak Yaacov, Tamar Shiloach, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 6, 2016
Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants
Hadas Weinstein-Marom, Aviad Pato, Noam Levin, et al.
Dermatologic Therapy
|
October 3, 2022
Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma
Rony Shreberk-Hassidim, Lilach Aizenbud, Shalev Lussheimer, et al.
The Journal of General Virology
|
May 25, 2012
Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity
Barak Yaacov, Itay Lazar, Shay Tayeb, et al.
Cancer Research
|
May 8, 2007
MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells
Jacobus J Bosch, James A Thompson, Minu K Srivastava, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 93) with videos related to
Sort By:
Page
of 10
Oncotarget
|
April 19, 2014
Pathways and therapeutic targets in melanoma
Emma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2024
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events
Limor Rubin, Aviv Talmon, Yaarit Ribak, et al.
Cancer Immunology, Immunotherapy : CII
|
June 27, 2009
Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells
Jacobus J Bosch, Uzoma K Iheagwara, Sarah Reid, et al.
Anticancer Research
|
February 27, 2026
Autologous Tumor Vaccination in Melanoma and Colon Cancer Patients With Recurrent Liver Metastases: A Case Series
Ofra Maimon, Benjamin Nisman, Inna Ben-David, et al.
Frontiers in Immunology
|
September 22, 2023
The future of affordable cancer immunotherapy
Niels Schaft, Jan Dörrie, Gerold Schuler, et al.
Journal of Virology
|
October 30, 2009
The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
Itay Lazar, Barak Yaacov, Tamar Shiloach, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 6, 2016
Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants
Hadas Weinstein-Marom, Aviad Pato, Noam Levin, et al.
Dermatologic Therapy
|
October 3, 2022
Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma
Rony Shreberk-Hassidim, Lilach Aizenbud, Shalev Lussheimer, et al.
The Journal of General Virology
|
May 25, 2012
Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity
Barak Yaacov, Itay Lazar, Shay Tayeb, et al.
Cancer Research
|
May 8, 2007
MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells
Jacobus J Bosch, James A Thompson, Minu K Srivastava, et al.
Page
of 10